US Bancorp DE Sells 3,413 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

US Bancorp DE reduced its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 74.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,202 shares of the company’s stock after selling 3,413 shares during the quarter. US Bancorp DE’s holdings in Castle Biosciences were worth $32,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. R Squared Ltd bought a new stake in Castle Biosciences in the 4th quarter worth approximately $42,000. Quest Partners LLC lifted its holdings in shares of Castle Biosciences by 54.4% in the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after acquiring an additional 1,522 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Castle Biosciences in the 3rd quarter valued at $140,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock valued at $158,000 after purchasing an additional 604 shares in the last quarter. Finally, Oak Harvest Investment Services bought a new position in shares of Castle Biosciences during the 4th quarter valued at $206,000. 92.60% of the stock is currently owned by institutional investors.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock opened at $20.49 on Wednesday. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The company’s fifty day simple moving average is $25.38 and its two-hundred day simple moving average is $28.49. The firm has a market cap of $573.86 million, a PE ratio of 102.46 and a beta of 0.98.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Robert W. Baird boosted their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Stephens reiterated an “overweight” rating and issued a $41.00 price objective on shares of Castle Biosciences in a report on Thursday, January 2nd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $40.00.

Insider Activity

In related news, Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Derek J. Maetzold sold 2,715 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $29.62, for a total transaction of $80,418.30. Following the transaction, the insider now directly owns 82,047 shares of the company’s stock, valued at $2,430,232.14. This represents a 3.20 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,204 shares of company stock valued at $1,055,988. Company insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.